-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D0WLOFjOcNvUo3vgBqij0GTwtptaUJxehjGTtmFoYZDgWULIJtDxDj7UZstMLxET OV1v9W1n7Wd/uYCWpUOD1Q== 0001406774-08-000103.txt : 20080818 0001406774-08-000103.hdr.sgml : 20080818 20080818165821 ACCESSION NUMBER: 0001406774-08-000103 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080814 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20080818 DATE AS OF CHANGE: 20080818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: China YCT International Group, Inc. CENTRAL INDEX KEY: 0000847464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 652954561 STATE OF INCORPORATION: FL FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-01950 FILM NUMBER: 081025583 BUSINESS ADDRESS: STREET 1: C/O AMERICAN UNION SECURITIES STREET 2: 100 WALL STREET, 15TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 BUSINESS PHONE: 212-232-0120 MAIL ADDRESS: STREET 1: C/O AMERICAN UNION SECURITIES STREET 2: 100 WALL STREET, 15TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 FORMER COMPANY: FORMER CONFORMED NAME: itLinkz Group, Inc. DATE OF NAME CHANGE: 20070406 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL TECHNOLOGY & INNOVATIONS INC /FL/ DATE OF NAME CHANGE: 19960118 FORMER COMPANY: FORMER CONFORMED NAME: SOUTHSTAR PRODUCTIONS INC DATE OF NAME CHANGE: 19960118 8-K 1 cyig8k08142008.htm cyig8k08142008.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_____________________

FORM 8-K
_____________________


CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NO.: 33-27610-A


Date of Report: August 14, 2008


CHINA YCT INTERNATIONAL GROUP, INC.
(Exact name of registrant as specified in its charter)

 
 
 
 
 
Delaware 65-2954561
(State of other jurisdiction of (IRS Employer
incorporation or organization) Indentification No.)
 
 
 

 
c/o American Union Securities, Inc. 100 Wall Street, 15th Floor, New York, N.Y. 10005
(Address of principal executive offices) (Zip Code)
 


 
212-232-0120
(Registrant’s telephone number including area code)






Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

        □   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
        □   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
□  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
□  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 

 
Item 1.02
Termination of a Material Definitive Agreement

 
On April 4, 2008, Shandong Spring Pharmaceutical Co., Ltd, a wholly-owned subsidiary of the Registrant, entered into an Entrusted Management Agreement with Shandong Yong Chun Tang Bioengineering Co. Ltd., effective as of April 1, 2008.  On the same date, the parties entered into a Purchase Option and Cooperation Agreement with Yan Tinghe, who is the Chairman of China YCT International Group, Inc. and principal owner of Shandong Yong Chun Tang.
 
 
On August 14, 2008 the parties agreed to rescind, ab initio, both the Entrusted Management Agreement and the Purchase Option and Cooperation Agreement.  The reason for the rescission was the parties’ discovery of a mutual mistake regarding the effect of the agreements on the ability of Shandong Yong Chun Tang Bioengineering Co. Ltd. to do business in China.  Since the mistake, if not corrected,  would have led to a material reduction in the benefit that the parties expected to obtain from the agreements, the parties have declared the agreements void.
 
 
Shandong Yong Chun Tang Bioengineering Co. Ltd. will continue to serve as the principal supplier of goods sold by Shandong Spring Pharmaceutical Co., Ltd.
 

SIGNATURES
 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
China YCT International Group, Inc.
 
Dated:  August 18, 2008
By:/s/ Yan Tinghe
   Yan Tinghe
    Chief Executive Officer
 



 -----END PRIVACY-ENHANCED MESSAGE-----